Introduction
adverse effects. This in turn results in a high therapeutic ratio as compared with systemic delivery by oral or parenteral routes of administration. Over the past The inhaled route of administration is the preferred route for delivering preventer and reliever drugs to decade the delivery of inhaled drugs has been continuously refined by inhaler delivery devices which optimise patients with airflow obstructions. The inhaled route allows the delivery of relatively small doses of drug the deposition of respirable particles. Why should we be interested in the pharmacokinetics directly to the airway achieving a high local concentration, whilst at the same time minimising systemic of inhaled drugs? The application of pharmacokinetics provides a valuable tool for investigating lung deposition enhanced delivery of salbutamol from a low velocity modified vortex metered-dose actuator (Spacehaler, and bioavailability, and hence ways of optimising drug delivery. At the same time, pharmacokinetic techniques Evans) resulted in a greater plasma C max compared with an ordinary actuator [2 ] . As one might perhaps predict, can be used to predict and explain the systemic adverse effect profiles of inhaled drugs. The widespread availthe higher plasma concentration of salbutamol was associated with a leftward shift in the dose-response ability of sensitive assay techniques, such as high performance liquid chromatography allows the measurecurve for extrapulmonary b 2 -mediated responses. The same methodology was subsequently used to compare ment of plasma and urinary drug levels required for pharmacokinetic evaluation. The purpose of this review two nebuliser delivery systems, namely the Hudson Updraft II and the Ventstream. In vitro studies had is to appraise the literature on pharmacokinetics of commonly used inhaled drugs and how this may be shown that the Ventstream produced a significant increase in output of respirable particles compared with applied to optimising their use in every-day clinical practice.
the Hudson [3] . Since the Venstream also increases the drug delivery by matching the nebuliser output to inspiratory tidal flow rate, one might expect to find a difference in lung deposition of salbutamol when comparing the two nebuliser systems. In a study of Inhaled b 2 -adrenoceptor agonists asthmatic patients (FEV 1 55% predicted ) [3 ] the Venstream produced an enhanced delivery of salbutamol Following inhalation of salbutamol, most of the dose (60-80%) is delivered to the oropharynx and hence to across a dose range of 1.25 mg, 2.5 mg and 5 mg, resulting in an approximate two-fold improvement in the gut after swallowing, with a much smaller fraction (10-20%) reaching the lungs. The polarity of salbutamol lung absorption as assessed by plasma C max or area under the concentration-time profile (AUC) (Figure 1 ). at salivary pH results in only negligible buccal absorption, and the swallowed fraction undergoes extensive
This was associated with a difference between nebulisers in AUC values for bronchodilator and systemic first-pass conjugation in the intestinal wall and liver. Since there is no first-pass conjugation in the lung, this responses. Furthermore, each nebuliser exhibited linear pharmacokinetics with doubling doses of salbutamol. means that initial plasma levels of unchanged salbutamol will reflect the dose delivered to the lung. Direct
The pharmacokinetic approach may also be applied to evaluate the bioequivalence of different formulations measurement of plasma salbutamol given by pressurised metered-dose inhaler shows that maximal plasma conof inhaled salbutamol. In one such study no differences were found in lung absorption of salbutamol comparing centration (C max ) is achieved within 5-10 min of inhalation, consistent with rapid absorption from the lung three different formulations of inhaled salbutamol given by pressurised metered dose inhaler [4] . However, in a [ 1, 2] . It is however, unclear what proportion of this initial absorption originates from alveolar or bronchial comparison of a non-CFC metered-dose inhaler formulation of salbutamol (Airomir, 3M ) with a CFC meteredsites. This approach provides a simple method to compare the relative drug deposition of salbutamol from dose inhaler formulation ( Ventolin, Allen & Hanburys), a 1.3-fold greater ratio for C max was found [5] different inhaler devices by making a direct measurement of lung absorption. In an initial study it was shown that ( Figure 2 ). This probably reflects the lower aerosol 1.8-fold greater compared with the same dose using an inhalation delay of 20 s [7] . These effects were mirrored by commensurate differences in extrapulmonary b 2 -adrenoceptor activity (Figure 3 ). The effects of multiple percentage for lung deposition if a standard intravenous injection of the same drug is used as a pharmacokinetic actuations and inhalation delay are similar to those observed in vitro for salbutamol, corticosteroids and internal standard for comparison. There appears to be good agreement between estimates of lung deposition of cromoglycate delivered by large volume spacer [8] [9] [10] . In vitro studies have also shown that reduction in terbutaline using pharmacokinetic and technetium radiolabel aerosol methods. electrostatic charge within the spacer using an antistatic lining is associated with a significant improvement in
In a pharmacokinetic study inhaled terbutaline in a dose of 250 mg produced a lung deposition of 19% delivery of respirable particles [11 ] . The pharmacokinetic technique was applied to show that washing the when administered by dry powder reservoir device (Turbuhaler, Astra) compared with 8% when delivered spacer is an effective way of eliminating such electrostatic charge and hence optimising drug delivery [ 7] .
by metered-dose inhaler [13] . At the same time a dose ratio of 251 was demonstrated in terms of equivalent An alternative, albeit indirect, method of evaluating pharmacokinetics of inhaled b 2 -adrenoceptor agonists bronchodilator response comparing 250 mg of terbutaline via a turbuhaler and 500 mg via a metered-dose inhaler. is to measure urinary excretion. One application of this technique involved the measurement of urinary excretion However, such dose ratios are better evaluated by performing proper dose-response studies providing this of inhaled terbutaline, using oral activated charcoal to eliminate the gastrointestinal component of systemic is done on the steep part of the curve. In one such study, the bronchodilator-dose response (measured as bioavailability [12 ] . This enables calculation of a FEV 1 ) showed a 1.5-fold dose-ratio comparing terbutaline given by turbuhaler and metered dose inhaler. Furthermore, the 1.5-fold greater ratio for bronchodilator efficacy was exactly mirrored by the ratio for hypokalaemic response, inferring that lung deposition determines both airway and systemic effects [14 ] .
Another indirect urinary pharmacokinetic method involves using the measurement of 30 min urinary excretion of salbutamol and its conjugates in order to differentiate between the components of lung and gastrointestinal absorption [15 ] . This premise depends on the assumption that most of the urinary excretion of unchanged salbutamol in the first 30 min after inhalation is due predominantly to absorption from the lungs. However, it is pertinent to note that in a study where it variability is approximately two-fold greater with the drugs, the main determinant of systemic bioavailability is that derived from the lung. Mouth rinsing, to reduce local urinary compared with the plasma method [4 ] . This adverse effects, will act to attenuate further the small suggests that given the availability of a sufficiently component of gut bioavailability.
sensitive assay, the direct measurement of plasma salbutamol is the preferred method to quantify absorption from lungs.
Inhaled corticosteroids On first principles, it might be predicted that lung deposition and hence, bioavailability from the lung, Surprisingly little has been published on the pharmacokinetics of inhaled corticosteroids. This probably reflects would be altered in patients with airflow obstruction as a consequence of reduced small airway calibre and the lack of widely available sensitive assays for measuring plasma levels. Earlier studies with tritium labelled hence reduced peripheral lung absorption. In this respect there are some data to show that asthmatics with a inhaled budesonide showed a plasma elimination halflife of 2.0 h [19] . Calculated values for oral budesonide 50% reduction in predicted normal FEV 1 have an approximate two-fold reduction in fenoterol C max comshowed a systemic bioavailability of 11% indicating a high degree of first-pass hepatic metabolism (89%) of pared with normals given the same dose (1.6 ng ml−1 in asthmatics vs 3.1 ng ml−1 in normals) [1, 16] . the swallowed dose. For the inhaled route the systemic bioavailability was calculated at 73% indicating a Furthermore the difference in plasma fenoterol concentration between the two groups was associated with a considerable absorption from the lung of the unchanged drug. This is in keeping with in vitro studies showing marked difference in the chronotropic response to fenoterol, being greater in the group of normal subjects.
extensive biotransformation in the liver but not at all in the lung [20] . For beclomethasone diproprionate partial This is in keeping with the observation that enhanced absorption from the lung is associated with increased biotransformation to beclomethasone-17-monopropionate, an active metabolite, occurs in both liver and systemic b 2 -adrenoceptor mediated effects [2 ] . The use of plasma pharmacokinetics has also been lung. Precise pharmacokinetic evaluation of the degree of liver and lung first-pass metabolism of beclomeemployed to evaluate the effect of inhaler technique on delivery of terbutaline by the dry powder reservoir thasone dipropionate in humans is not available. However, in terms of hepatic first-pass metabolism of inhaler system [17 ] . These results show that lung volume prior to inhalation had no effect on lung the swallowed dose, data from a recent study using oral activated charcoal, revealed approximately 60-70% absorption when used with a peak inspiratory flow rate in excess of 60 l min−1. At an inspiratory flow rate of first-pass hepatic inactivation [21 ] . Fluticasone proprionate like budesonide has no lung first-pass metab-30 l min−1 drug absorption was reduced to a small degree, and the bronchodilator dose-response curve was olism, but has 99% hepatic first-pass metabolism of the swallowed dose [22 ] . not significantly altered. When subjects first exhaled into the turbuhaler prior to inhalation, there was a Therefore it is the lung rather than the gut component of absorption which will be the main determinant of the marked reduction in plasma levels and this was accompanied by a commensurate right shift in the overall systemic bioavailability, at least for budesonide and fluticasone propionate where there is extensive bronchodilator dose-response curve as well as systemic b 2 -mediated effects. Improvements in drug delivery to hepatic first-pass but no lung first-pass metabolism ( Figure 4 ). For beclomethasone dipropionate the lower the lung using 30 min urinary salbutamol excretion have been shown with a metered dose inhaler in association degree of hepatic first-pass inactivation results in the swallowed fraction of the inhaled dose assuming greater with exhaling to residual volume, slow inhalation and breath holding [18 ] .
importance in determining the systemic activity profile.
The differences in the hepatic first-pass inactivation for lung deposition appears to translate into a commensurate dose-ratio for clinical efficacy. In a double-blind therefore explain the observation that for budesonide the addition of a large volume spacer to a metered dose randomized double-dummy cross over study of 241 stable asthmatic children, halving their dose of budesoninhaler will increase systemic bioactivity ( by increasing lung absorption), whilst for beclomethasone diproprionide via the nebuhaler resulted in a clinical relapse in 126 cases [26 ] . Of these 126 patients, 64 were ranate the addition of a spacer reduces systemic activity ( by reducing gut absorption). In other words, for domized to continue with their usual budesonide dose via the nebuhaler, with the other 62 being randomized beclomethasone dipropionate the reduction in gastrointestinal absorption with the spacer outweighs the to use half their usual dose via the turbuhaler. After 9 weeks of evaluation, there were no differences between concomitant increase in lung absorption, because of the low degree of hepatic first-pass inactivation. Thus, for the two groups in terms of symptom control, spirometry, peak flow rate or exercise challenge. A similar degree of fluticasone propionate like budesonide, the use of a large volume spacer would increase systemic bioactivity, corticosteroid dose-reduction for turbuhaler vs nebuhaler has been reported during step-down therapy to because lung absorption is the major determinant, and this would be increased with the spacer. In any event, identify the lowest maintenance dose of inhaled budesonide over a prospective 4 year period of follow-up in mouth-rinsing should be routinely employed when using inhaled corticosteroids to reduce local adverse effects asthmatic children [27] . This suggests that at least with inhaled budesonide, greater lung deposition with the such as oropharyngeal candidiasis. This in turn acts to reduce further the component of gut bioavailability.
turbuhaler allows lower maintenance doses during the step-down phase of the management guidelines. Detailed studies have evaluated the plasma pharmacokinetics of inhaled budesonide in children and adults.
The pharmacokinetics of inhaled corticosteroids may also determine the systemic adverse effect profile, In a study of adult healthy volunteers a single 1000 mg dose of budesonide was given via a turbuhaler or particularly for drugs such as budesonide and fluticasone propionate which have high hepatic first-pass, but no metered dose inhaler along with intravenous administration of a 500 mg dose of budesonide as a reference lung first-pass metabolism. Fluticasone propionate has approximately 2-3 times greater glucocorticoid potency [ 23] . The same treatments were also administered with concomitant oral charcoal to obviate gastrointestinal than budesonide [28 ] . Thus if lung absorption is the major determinant of systemic bioactivity, one might absorption and hence evaluate the bioavailability from the lung. The pharmacokinetic profile for both inhaler expect to find commensurate differences between the two drugs in terms of their respective systemic bioactivdevices showed rapid absorption with a t max for budesonide of 0.3 h and elimination half-life of 2.3 h. In ity. This hypothesis was investigated in a comparison of single inhaled doses of budesonide and fluticasone the presence of charcoal-block the lung bioavailability was calculated at 32% for the turbuhaler vs 18% for ranging from 400-2000 mg, both given by metered-dose aerosol with mouth rinsing to asthmatic adults in a the metered dose inhaler. Comparative values for total bioavailability in the absence of charcoal (i.e. lung plus placebo controlled double-blind randomized cross-over study [29] . Suppression of overnight urinary cortisol gut) were 38% for the turbuhaler against 26% for the metered dose inhaler, giving a clear indication of the excretion, a sensitive marker of adrenal activity, showed approximately two-fold greater suppression with flutrelative lung and gut components.
In asthmatic children given inhaled (1000 mg) and icasone 500 mg than with budesonide 400 mg. For 08.00 h serum cortisol and ACTH, at doses above 1000 mg on intravenous (500 mg ) doses of budesonide without charcoal, total systemic bioavailability was calculated at the steep part of the dose-response curve there was three-fold greater adrenal suppression with fluticasone approximately 30% of the nominal inhaled dose from a tube spacer (Inhalet) and 15% from a nebuliser (Parithan with budesonide on a mg equivalent basis. Similar differences in systemic activity have been found comparinhalerboy) [24 ] . Data from the same study revealed a value for clearance of budesonide which was 40% higher ing single inhaled doses of fluticasone and budesonide (400-1250 mg) given by spacer to asthmatic children, than comparable values in adults, along with a shorter elimination half-life of 1.5 h. The higher clearance and with three-fold greater suppression of urinary cortisol excretion [30 ] . shorter half-life of budesonide in children would seem to be advantageous in terms of reducing the burden of Thus it is evident that lung absorption of a corticosteroid with enhanced potency produces greater systemic systemic adverse effects.
The charcoal-block method has also been used to activity on the steep part of the dose-response curve. The plasma elimination half-life of inhaled budesonide investigate the pharmacokinetics of plasma budesonide given as a 1000 mg dose via a turbuhaler to asthmatic is 2.3 h compared with 14.4 h for inhaled fluticasone [23, 31] . The longer elimination half-life for fluticasone children. It was found that charcoal reduced the systemic absorption (as AUC (0,4 h)) by approximately 20%. The should result in greater steady-state accumulation during repeated dosing. This is supported by a study where absorption of the same dose of budesonide was higher comparing turbuhaler with nebuhaler ( both without there was a large step-up in adrenal suppression between single and repeated doses of fluticasone 1000 mg twice charcoal ) being two-fold greater [ 25] . Allowing for greater oropharangeal deposition of budesonide with a daily (25% vs 55% suppression), whereas with budesonide 800 mg twice daily this effect was much less turbuhaler than with a nebuhaler, these data suggest an almost two-fold greater lung delivery of budesonide pronounced (26% vs 34% suppression) [32 ] . Other factors which may contribute to greater steady-state when comparing the two devices. Interestingly, this ratio suppression with fluticasone include a more prolonged three-fold difference in AUC (0,240 min), and was mirrored by similar differences in C max . There were receptor residency time [33 ] and greater lipophilicity [ 34] compared with either budesonide or beclomehowever, no differences in plasma concentration-time curves when comparing inhalation from a spinhaler thasone dipropionate. The higher degree of lipophilicity for fluticasone may result in enhanced systemic tissue with and without a 10 s breath hold at the end of inspiration. In the same study pharmacokinetics of retention in fat stores, in effect acting as a reservoir in the body at steady-state.
sodium cromoglycate delivered as a solution directly into the airways was investigated in patients undergoing diagnostic bronchoscopy. The plasma concentrationtime profile was found to be similar to those obtained after normal inhalation and values for C max and Inhaled sodium cromoglycate and nedocromil sodium AUC(0,240 min) were intermediate between the higher two inspiratory flow rates for the spinhaler. Comparison The pharmacokinetics of inhaled sodium cromoglycate and nedocromil sodium has been extensively evaluated of the AUC values after bronchoscopic administration with those by spinhaler indicates that only 10% of the both in normal subjects and in patients with obstructive airways disease. After inhalation of sodium cromoglycate nominal dose reaches the airways. Furthermore comparison of the AUC after bronchoscopic administration there is rapid absorption from the alveolar vascular bed with peak plasma levels being reached within 20 min with that after intravenous infusion suggests that approximately 70% of the drug was bioavailable in [35] [36] [37] [38] .
However absorption appears to occur at two different terms of absorption from the lungs. The effects of bronchoconstrictor challenge with rates with an initial fast phase from the alveoli and a later slow phase from the bronchial epithelium. This methacholine, histamine and adenosine monophosphate (AMP) on the pharmacokinetics of inhaled sodium slower phase of absorption is probably due to the high degree of hydrophilicity of sodium cromoglycate which cromoglycate have been evaluated in a series of studies from the same laboratory. Methacholine challenge results in a lesser propensity for absorption from the bronchial epithelial barrier compared with the endoresulted in a 23% lower FEV 1 and a 2.8-fold higher central5peripheral lung deposition ratio (with thelium of the alveolar vascular bed. Thus, inhaled sodium cromoglycate exhibits absorption rate-limited technetium-99m) in comparison with saline [ 41] . Inhalation of methacholine was associated with signifior 'flip-flop' kinetics, as has been shown by comparison of elimination after intravenous and inhaled dosing cant increase in C max but not in AUC for plasma cromoglycate. The greater C max after methacholine is [35] [36] [37] .
The urinary excretion of sodium cromoglycate given difficult to explain if initial rapid absorption occurs from the peripheral alveolar vascular bed, particularly by dry powder inhaler (Spinhaler, Fisons) has been used to evaluate the effect of airway calibre on lung since technetium studies suggested increased central deposition after methacholine inhalation. bioavailability in patients with obstructive airways disease compared with normal controls [ 39] . Urinary
The effects of inspiratory flow rate on pharmacokinetics of sodium cromoglycate given by spinhaler and excretion as a measure lung bioavailability is possible, because when sodium cromoglycate is given orally less its protection against AMP challenge were evaluated in asthmatic subjects [42 ] . Values for C max and AUC than 2% is absorbed, and when given by the intravenous or inhaled route the drug is also excreted unmetabolized.
showed proportional attenuation with associated reduction in inspiratory flow rate. Furthermore, both It was found that urinary excretion of sodium cromoglycate was markedly reduced in patients with chronic inspiratory flow rate and AUC correlated significantly with the degree of protection afforded against AMP bronchitis but not in asthmatics as compared with normal controls. The explanation for this may be the induced bronchoconstriction. This shows that the inspiratory flow rate used to inhale sodium cromoglycate combined effects of a lower FEV 1 and a lower inspiratory flow rate in the chronic bronchitic compared with dry powder is an important determinant of protection against bronchial challenge. The smaller degree of lung asthmatic group, resulting in reduced lung bioavailability. However in another study looking at lung absorption at lower inspiratory flow rates probably reflects a reduction in fragmentation of particles in the bioavailability of sodium cromoglycate given via a spinhaler, there was a reduction in plasma C max and spinhaler device and hence a lower delivered mass of respirable particles. AUC comparing asthmatic patients vs normal volunteers, and this was also mirrored by urinary excretion
In another study following histamine inhalation which produced a 20% fall in FEV 1 , initial absorption of [ 40] . There was a large inter-subject variability in plasma concentration of sodium cromoglycate which sodium cromoglycate from lung was significantly increased as evidenced by lower values for t max and was attributed to differences in inhalation technique, particularly with respect to inspiratory flow rate and absorption half-life [43] . This phenomenon was observed in both histamine non-responsive (control breath holding.
In a study of normal subjects using the spinhaler normal subjects) and hyperresponsive subjects and was therefore independent of bronchoconstriction. The sugthere were clear differences in plasma concentration time curves for three different peak inspiratory flow gested mechanism for enhanced initial absorption of sodium cromoglycate was an increase in permeability of rates [37] . For example, mean inspiratory flow rates of 57 l min−1 and 184 l min−1 resulted in an approximate the bronchial epithelium due to histamine. This in turns suggests that the pharmacokinetics of inhaled sodium attempted to evaluate pharmacokinetics for inhaled delivery of aminoglycoside antibiotics. The polarity of cromoglycate may be altered by inflammatory mediators present at the site of drug absorption from the airways, gentamicin is such that it is poorly absorbed from the gastrointestinal tract. Hence plasma levels of gentamicin although the effect appears to be relatively short-lived and not clinically relevant. The plasma pharmacokinetics following inhalation will directly reflect absorption from the lungs. However, as with cromoglycate, a high degree of cromoglycate have also been investigated in tandem with its effects on exercise induced bronchoconstriction, of hydrophilicity may result in a greater propensity for absorption across the endothelium of the alveolar with a ceiling in response being observed at inhaled doses which resulted in plasma levels of about 4 ng ml−1 vascular bed compared with the bronchial mucosa. In one study, serum levels of gentamicin 1 h post-dosing [ 44] . This illustrates the point that the plasma concentration is not directly related to the local doseranged from 3.0 to 12.0 mg ml−1 after intramuscular administration and 1.3 to 6.8 mg ml−1 after intratracheal response effect.
The pharmacokinetics of inhaled nedocromil sodium administration, both given in a daily dose of 240 mg [50] . In a study of four patients, 40 mg of nebulised are similar to those of sodium cromoglycate in that it exhibits two absorption components consistent with a gentamicin achieved mean levels of 22.2 mg ml−1 in tracheal aspirate and 0.2 mg ml−1 in serum [ 51], 'flip-flop' model [ 45] . As is the case with cromoglycate, the terminal half-life of nedocromil represents the although no details of nebuliser apparatus or sampling times are available. Thirty minutes after intratracheal absorption half-life, with absorption from the lungs becoming rate limiting. After inhalation of 4 mg dose administration, mean peak serum concentration of gentamicin was 1.04 mg ml−1, with levels in bronchial by a pressurised metered dose inhaler, differences were observed between normal volunteers and asthmatic secretions at 4 h (43 mg ml−1) exceeding minimum bacterial inhibitory concentrations. Serum gentamicin patients in terms of a prolonged t max and lower values for C max and AUC in the asthmatics [45 ] . The calculated levels have also been measured 1 h after an 80 mg dose given via a nebuliser, via oral aerosolisation or via a bioavailability for inhaled nedocromil was 9.2% of the nominal dose in normals vs 5.7% in asthmatics. As with tracheotomy tube, both with intermittent positive pressure breathing [ 52] . Serum gentamicin levels were 0.1 to cromoglycate absorption of an oral dose is less than 2%. With inhalation of both cromoglycate and nedocro-0.94 mg ml−1 after tracheal aerosolisation and 0.1 to 0.16 mg ml−1 after normal inhalation. Moreover, 1 h mil, forced expiration and deep inspiration results in enhanced drug absorption [46, 47] . It has also been after nasotracheal administration of gentamicin levels ranged from 1.2 to 4.0 mg ml−1. Serum concentration of found that significant increases in plasma nedocromil concentration occurs following exercise but not after gentamicin, were evaluated 1 h after intramuscular (1.5 mg kg−1), intratracheal (40 mg) and oral nebulised valsalva manoeuvres or hyperventilation, suggesting that enhanced bioavailability occurs as a consequence (40 mg) administration to children with cystic fibrosis [53] . Mean serum concentration of gentamicin was of an increase in lung volume with exercise [48] . In a comparison of a intravenous and inhaled nedocromil much lower after aerosolised (0.20 mg ml−1) than intratracheal (0.53 mg ml−1) routes. Both aerosolised and during AMP challenge no relationship was found between either C max or AUC and protection against intratracheal routes gave adequate bronchial levels above minimum bacterial inhibitory concentration. AMP bronchoconstriction [49] . Since inhaled but not systemic administration of nedocromil produced protecNebulised delivery of tobramycin in a single-dose of 120 mg achieved sputum levels in excess of 100 mg ml−1 tion, there is no direct relationship between plasma levels and degree of protection afforded against in patients with cystic fibrosis [54 ] . Taken together, these studies suggest that therapeutic challenge.
nebulised doses of gentamicin achieve adequate levels in the bronchial tree with only minimal systemic absorption. It is unclear whether it is possible to evaluate lung delivery of gentamicin with different Other inhaled drugs nebulisers using pharmacokinetic methods, since this would require a proper concentration-time profile to The nebulised route of delivery now has an established role for delivering antibiotics to the lung in patients quantify accurately lung absorption. Delivery of nebulised morphine to the lung has been with the chronic bronchial sepsis as well as to delivery pentamidine prophylaxis for patients with HIV infection.
suggested as a way of avoiding hepatic first-pass metabolism and an alternative method for achieving The type of nebuliser is important in determining the size of particles and preferred site of distribution for rapid analgesia compared with the oral or prarenteral route of administration. It has also been suggested that delivery of the drug. For example, in delivering nebulised pentamidine it is more preferable to produce peripheral it may relieve breathlessness in patients with associated bronchial carcinoma by a direct action on airway deposition to the alveolar compartment of the lung. It would therefore seem appropriate in these situations to nociceptive receptors. In a recent study the pharmacokinetics of morphine were compared when given by the apply the pharmacokinetic technique for evaluating drug delivery in order to compare different nebuliser intravenous, oral and nebulised routes of administration to 10 healthy subjects [55] . Nebulised delivery of systems, as has successfully been done with nebulised salbutamol [3 ] . morphine was associated with an initial rapid absorption from the lung with a t max of 10 min and a time profile There have been a number of studies which have salbutamol metered dose inhalers. T horax 1996; 51: similar to that of the intravenous route. The systemic 325-326. bioavailability of morphine calculated from the AUC 
